Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23363341,maximum plasma concentration,The maximum plasma concentration was 109.4 ng/mL at 2.15 hours.,Pharmacokinetics of long-acting nalbuphine decanoate after intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363341/),[ng] / [ml],109.4,4985,DB00844,Nalbuphine
,23363341,terminal half-life,The mean terminal half-life was 20.4 hours.,Pharmacokinetics of long-acting nalbuphine decanoate after intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363341/),h,20.4,4986,DB00844,Nalbuphine
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00844,Nalbuphine
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00844,Nalbuphine
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00844,Nalbuphine
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00844,Nalbuphine
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00844,Nalbuphine
,28903824,Tmax,"Nalbuphine was absorbed more quickly when administered subcutaneously (Tmax, 5 min) than intraperitoneally (Tmax, 10 min), whereas the drug's half-life was similar between the intraperitoneal (0.94 h) and subcutaneous (1.12 h) routes.",Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903824/),min,5,21574,DB00844,Nalbuphine
,28903824,Tmax,"Nalbuphine was absorbed more quickly when administered subcutaneously (Tmax, 5 min) than intraperitoneally (Tmax, 10 min), whereas the drug's half-life was similar between the intraperitoneal (0.94 h) and subcutaneous (1.12 h) routes.",Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903824/),min,10,21575,DB00844,Nalbuphine
,28903824,half-life,"Nalbuphine was absorbed more quickly when administered subcutaneously (Tmax, 5 min) than intraperitoneally (Tmax, 10 min), whereas the drug's half-life was similar between the intraperitoneal (0.94 h) and subcutaneous (1.12 h) routes.",Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903824/),h,0.94,21576,DB00844,Nalbuphine
,28903824,half-life,"Nalbuphine was absorbed more quickly when administered subcutaneously (Tmax, 5 min) than intraperitoneally (Tmax, 10 min), whereas the drug's half-life was similar between the intraperitoneal (0.94 h) and subcutaneous (1.12 h) routes.",Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903824/),h,1.12,21577,DB00844,Nalbuphine
,3060191,Plasma concentrations,"4. Plasma concentrations of nalbuphine expressed as morphine equivalents ranged from 5 to 52 ng ml-1, indicating considerable mu-opiate affinity.","Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3060191/),[ng] / [ml],5 to 52,48419,DB00844,Nalbuphine
,25885112,half-life,"Mean half-life was 14.2 hours, mean Cmax and AUCtau ranged between 13 and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion.",Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25885112/),h,14.2,56397,DB00844,Nalbuphine
,25885112,Cmax,"Mean half-life was 14.2 hours, mean Cmax and AUCtau ranged between 13 and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion.",Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25885112/),[ng] / [ml],13 and 83,56398,DB00844,Nalbuphine
,25885112,AUCtau,"Mean half-life was 14.2 hours, mean Cmax and AUCtau ranged between 13 and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion.",Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25885112/),[ng∙h] / [ml],118,56399,DB00844,Nalbuphine
,25885112,AUCtau,"Mean half-life was 14.2 hours, mean Cmax and AUCtau ranged between 13 and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion.",Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25885112/),[ng∙h] / [ml],76,56400,DB00844,Nalbuphine
,21310722,clearance,"Population parameter estimates were: clearance 130 litre h(-1) 70 kg(-1), inter-compartment clearance 75.6 litre h(-1) 70 kg(-1), central volume of distribution 210 litre 70 kg(-1), and peripheral volume of distribution 151 litre 70 kg(-1).",Population pharmacokinetics of nalbuphine after surgery in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310722/),[l] / [70·h·kg],130,58281,DB00844,Nalbuphine
,21310722,inter-compartment clearance,"Population parameter estimates were: clearance 130 litre h(-1) 70 kg(-1), inter-compartment clearance 75.6 litre h(-1) 70 kg(-1), central volume of distribution 210 litre 70 kg(-1), and peripheral volume of distribution 151 litre 70 kg(-1).",Population pharmacokinetics of nalbuphine after surgery in children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310722/),[l] / [70·h·kg],75.6,58282,DB00844,Nalbuphine
,21310722,central volume of distribution,"Population parameter estimates were: clearance 130 litre h(-1) 70 kg(-1), inter-compartment clearance 75.6 litre h(-1) 70 kg(-1), central volume of distribution 210 litre 70 kg(-1), and peripheral volume of distribution 151 litre 70 kg(-1).",Population pharmacokinetics of nalbuphine after surgery in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310722/),[l] / [70·kg],210,58283,DB00844,Nalbuphine
,21310722,peripheral volume of distribution,"Population parameter estimates were: clearance 130 litre h(-1) 70 kg(-1), inter-compartment clearance 75.6 litre h(-1) 70 kg(-1), central volume of distribution 210 litre 70 kg(-1), and peripheral volume of distribution 151 litre 70 kg(-1).",Population pharmacokinetics of nalbuphine after surgery in children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310722/),[l] / [70·kg],151,58284,DB00844,Nalbuphine
,3691617,concentrations,"Mean plasma nalbuphine concentrations 5 min after intravenous administration of 10 or 20 mg were 39 and 73 ng/ml, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [m],39,65345,DB00844,Nalbuphine
,3691617,concentrations,"Mean plasma nalbuphine concentrations 5 min after intravenous administration of 10 or 20 mg were 39 and 73 ng/ml, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [m],73,65346,DB00844,Nalbuphine
,3691617,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) after intramuscular or subcutaneous administration of nalbuphine 10 mg were 29 and 31 ng/ml, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [ml],29,65347,DB00844,Nalbuphine
,3691617,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) after intramuscular or subcutaneous administration of nalbuphine 10 mg were 29 and 31 ng/ml, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [ml],31,65348,DB00844,Nalbuphine
,3691617,Cmax,Mean Cmax values after 20 mg doses were 60 and 56 ng/ml.,"The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [ml],60,65349,DB00844,Nalbuphine
,3691617,Cmax,Mean Cmax values after 20 mg doses were 60 and 56 ng/ml.,"The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[ng] / [ml],56,65350,DB00844,Nalbuphine
,3691617,elimination half-lives,"The mean elimination half-lives of parenterally administered nalbuphine ranged between 2.2 and 2.6 h, regardless of dose given or route administered.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),h,2.2 and 2.6,65351,DB00844,Nalbuphine
,3691617,absolute bioavailability,"The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),%,81,65352,DB00844,Nalbuphine
,3691617,absolute bioavailability,"The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),%,83,65353,DB00844,Nalbuphine
,3691617,absolute bioavailability,"The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),%,79,65354,DB00844,Nalbuphine
,3691617,absolute bioavailability,"The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),%,76,65355,DB00844,Nalbuphine
,3691617,volumes of distribution (Vss),"The mean volumes of distribution (Vss) of the intravenously administered drug were 290 and 274 l and the mean systemic clearances were 1.6 and 1.5 l/min following administration of 10 and 20 mg doses, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),l,290,65356,DB00844,Nalbuphine
,3691617,volumes of distribution (Vss),"The mean volumes of distribution (Vss) of the intravenously administered drug were 290 and 274 l and the mean systemic clearances were 1.6 and 1.5 l/min following administration of 10 and 20 mg doses, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),l,274,65357,DB00844,Nalbuphine
,3691617,systemic clearances,"The mean volumes of distribution (Vss) of the intravenously administered drug were 290 and 274 l and the mean systemic clearances were 1.6 and 1.5 l/min following administration of 10 and 20 mg doses, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[l] / [min],1.6,65358,DB00844,Nalbuphine
,3691617,systemic clearances,"The mean volumes of distribution (Vss) of the intravenously administered drug were 290 and 274 l and the mean systemic clearances were 1.6 and 1.5 l/min following administration of 10 and 20 mg doses, respectively.","The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691617/),[l] / [min],1.5,65359,DB00844,Nalbuphine
,21627518,terminal half-life,Nalbuphine was rapidly eliminated with a terminal half-life of 0.33 hours and clearance of 69.95 mL/min/kg after IV administration and a half-life of 0.35 hours after IM administration.,Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627518/),h,0.33,77998,DB00844,Nalbuphine
,21627518,clearance,Nalbuphine was rapidly eliminated with a terminal half-life of 0.33 hours and clearance of 69.95 mL/min/kg after IV administration and a half-life of 0.35 hours after IM administration.,Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627518/),[ml] / [kg·min],69.95,77999,DB00844,Nalbuphine
,21627518,half-life,Nalbuphine was rapidly eliminated with a terminal half-life of 0.33 hours and clearance of 69.95 mL/min/kg after IV administration and a half-life of 0.35 hours after IM administration.,Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627518/),h,0.35,78000,DB00844,Nalbuphine
,21627518,Volume of distribution,Volume of distribution was 2.01 L/kg after IV administration.,Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627518/),[l] / [kg],2.01,78001,DB00844,Nalbuphine
,21627518,fraction of the dose absorbed,The fraction of the dose absorbed was high (1.03) after IM administration.,Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21627518/),,1.03,78002,DB00844,Nalbuphine
,9107559,time to achieve the maximum plasma concentration (Cmax,The mean time to achieve the maximum plasma concentration (Cmax = 24 +/- 15 ng/mL) was 25 +/- 11 min and the elimination half-life was 2.7 +/- 0.7 h.,Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107559/),[ng] / [ml],24,84208,DB00844,Nalbuphine
,9107559,time to achieve the maximum plasma concentration (Cmax,The mean time to achieve the maximum plasma concentration (Cmax = 24 +/- 15 ng/mL) was 25 +/- 11 min and the elimination half-life was 2.7 +/- 0.7 h.,Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107559/),min,25,84209,DB00844,Nalbuphine
,9107559,elimination half-life,The mean time to achieve the maximum plasma concentration (Cmax = 24 +/- 15 ng/mL) was 25 +/- 11 min and the elimination half-life was 2.7 +/- 0.7 h.,Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107559/),h,2.7,84210,DB00844,Nalbuphine
greater,1797849,recoveries,The recoveries of buprenorphine and nalbuphine (internal standard) were greater than 90%.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),%,90,95107,DB00844,Nalbuphine
,1797849,limit of detection,The limit of detection was 1.0 ng/ml of plasma based on a signal-to-noise ratio of 3.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ng] / [ml],1.0,95108,DB00844,Nalbuphine
,1797849,signal-to-noise ratio,The limit of detection was 1.0 ng/ml of plasma based on a signal-to-noise ratio of 3.,Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),,3,95109,DB00844,Nalbuphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,1.32,95110,DB00844,Nalbuphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95111,DB00844,Nalbuphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95112,DB00844,Nalbuphine
,1797849,distribution,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,0.94,95113,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,1.32,95114,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95115,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95116,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],224,95117,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,0.94,95118,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,12.5,95119,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,232,95120,DB00844,Nalbuphine
,1797849,elimination half-lives,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],30,95121,DB00844,Nalbuphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,24.8,95122,DB00844,Nalbuphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,230,95123,DB00844,Nalbuphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],224,95124,DB00844,Nalbuphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),min,232,95125,DB00844,Nalbuphine
,1797849,clearance,"The two distribution and elimination half-lives and the clearance of buprenorphine were 1.32, 24.8 and 230 min and 224 ml/min in human plasma, and 0.94, 12.5 and 232 min and 30 ml/min in rabbit plasma.",Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797849/),[ml] / [min],30,95126,DB00844,Nalbuphine
,2758732,Elimination half-life (t1/2),Elimination half-life (t1/2) was significantly shorter in group I (0.9 hour) than it was in group II (1.9 hours) and in group III (2.3 hours).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),h,0.9,99316,DB00844,Nalbuphine
,2758732,Elimination half-life (t1/2),Elimination half-life (t1/2) was significantly shorter in group I (0.9 hour) than it was in group II (1.9 hours) and in group III (2.3 hours).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),h,1.9,99317,DB00844,Nalbuphine
,2758732,Elimination half-life (t1/2),Elimination half-life (t1/2) was significantly shorter in group I (0.9 hour) than it was in group II (1.9 hours) and in group III (2.3 hours).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),h,2.3,99318,DB00844,Nalbuphine
,2758732,Absolute bioavailability,Absolute bioavailability of nalbuphine increased from F = 12% in group II to 46.3% in group III (p less than 0.01).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),%,12,99319,DB00844,Nalbuphine
,2758732,Absolute bioavailability,Absolute bioavailability of nalbuphine increased from F = 12% in group II to 46.3% in group III (p less than 0.01).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),%,46.3,99320,DB00844,Nalbuphine
,2758732,F,Absolute bioavailability of nalbuphine increased from F = 12% in group II to 46.3% in group III (p less than 0.01).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),%,12,99321,DB00844,Nalbuphine
,2758732,F,Absolute bioavailability of nalbuphine increased from F = 12% in group II to 46.3% in group III (p less than 0.01).,"Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758732/),%,46.3,99322,DB00844,Nalbuphine
,9766863,flow-rate,A flow-rate of 1.2 ml/min at 20 degrees C was used.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),[ml] / [min],1.2,101441,DB00844,Nalbuphine
,9766863,limit of detection,The limit of detection of morphine was 100 pg/ml of plasma.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),[pg] / [ml],100,101442,DB00844,Nalbuphine
,9766863,absolute recoveries,The absolute recoveries of morphine and nalbuphine (internal standard) were between 86 and 89% and independent of morphine concentration.,Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),%,86 and 89,101443,DB00844,Nalbuphine
,9766863,absorption,"The absorption and elimination half-lives were 2.46 and 1.80 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,2.46,101444,DB00844,Nalbuphine
,9766863,elimination half-lives,"The absorption and elimination half-lives were 2.46 and 1.80 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,1.80,101445,DB00844,Nalbuphine
,9766863,distribution,"The distribution and elimination half-lives were 0.5 and 33.8 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,0.5,101446,DB00844,Nalbuphine
,9766863,elimination half-lives,"The distribution and elimination half-lives were 0.5 and 33.8 h, respectively.",Determination of morphine by high-performance liquid chromatography with electrochemical detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766863/),h,33.8,101447,DB00844,Nalbuphine
,28741675,bioavailability,The bioavailability of nalbuphine from intramuscularly injected DNS relative to that from nalbuphine HCl was 85.4%.,Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741675/),%,85.4,103039,DB00844,Nalbuphine
,28741675,mean absorption time,The mean absorption time of nalbuphine from DNS was 145.2 h.,Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741675/),h,145.2,103040,DB00844,Nalbuphine
,3358889,elimination half-life,"After i.v. administration, elimination half-life was 222 (111-460) min (mean and range) and total body clearance was 1.5 (0.8-2.3) 1 min-1.",The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358889/),min,222,111168,DB00844,Nalbuphine
,3358889,total body clearance,"After i.v. administration, elimination half-life was 222 (111-460) min (mean and range) and total body clearance was 1.5 (0.8-2.3) 1 min-1.",The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358889/),[1] / [min],1.5,111169,DB00844,Nalbuphine
,3358889,Cmax,Cmax after oral administration was 21.4 (6.0-36.2) ng ml-1 and tmax was 46.6 (15.3-89.0) min.,The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358889/),[ng] / [ml],21.4,111170,DB00844,Nalbuphine
,3358889,tmax,Cmax after oral administration was 21.4 (6.0-36.2) ng ml-1 and tmax was 46.6 (15.3-89.0) min.,The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358889/),min,46.6,111171,DB00844,Nalbuphine
,3358889,Bioavailability,Bioavailability of the oral preparation was 11.8 (6.1-20.1)%.,The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358889/),%,11.8,111172,DB00844,Nalbuphine
,15842759,recovery,The mean recovery for nalmefene was 80% in human plasma.,Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),%,80,111209,DB00844,Nalbuphine
,15842759,area under curve for 0 to 24 h,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ng)(ml],1116,111210,DB00844,Nalbuphine
,15842759,plasma clearance,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ml)(min],67.9,111211,DB00844,Nalbuphine
,3429694,plasma concentration,"The mean nalbuphine plasma concentration five minutes after 10 mg intravenously was 53 ng/mL, and the half-life of nalbuphine with this route of administration was 2.3 hours.",The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429694/),[ng] / [ml],53,128529,DB00844,Nalbuphine
,3429694,half-life,"The mean nalbuphine plasma concentration five minutes after 10 mg intravenously was 53 ng/mL, and the half-life of nalbuphine with this route of administration was 2.3 hours.",The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429694/),h,2.3,128530,DB00844,Nalbuphine
,3429694,maximum nalbuphine concentrations (Cmax),"In contrast, mean maximum nalbuphine concentrations (Cmax) after the three orally administered preparations ranged from 14.4 to 15.5 ng/mL, and occurred 0.9 to 1.2 hours after dose administration.",The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429694/),[ng] / [ml],14.4 to 15.5,128531,DB00844,Nalbuphine
,3429694,elimination half-lives,"Mean elimination half-lives after administration of the three nalbuphine oral formulations were essentially identical, ranging from 6.9 to 7.7 hours.",The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429694/),h,6.9 to 7.7,128532,DB00844,Nalbuphine
,3429694,Absolute bioavailability,Absolute bioavailability of the orally administered forms of nalbuphine ranged from 16.4 to 17.4% and Cmax and AUC data further established the bioequivalence of the three oral formulations.,The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429694/),%,16.4 to 17.4,128533,DB00844,Nalbuphine
,11076077,elimination half-life,Pharmacokinetic analysis revealed that SDN followed a linear one-compartment model with an elimination half-life of 74.7 min.,"High-performance liquid chromatographic method for the simultaneous determination of nalbuphine and its prodrug, sebacoyl dinalbuphine ester, in dog plasma and application to pharmacokinetic studies in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076077/),min,74.7,143892,DB00844,Nalbuphine
,3245223,bioavailability,"2. In dog, administration of the acetylsalicylate analogue increased nalbuphine bioavailability 5-fold to 16% and this correlated with an increase in analgesic activity.",Species variation in the disposition of nalbuphine and its acetylsalicylate ester analogue. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245223/),%,16,145390,DB00844,Nalbuphine
,23931676,T½,Plasma NAL concentrations were only detectable for 3 h postadministration (T½ = 0.68 h; Range: 0.53-0.79 h).,Pharmacokinetics and effect of intravenous nalbuphine in weaned Holstein calves after surgical castration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23931676/),h,0.68,147637,DB00844,Nalbuphine
greater,3410891,recovery,The recovery of nalbuphine and naltrexone (internal standard) was greater than 90%.,Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410891/),%,90,148229,DB00844,Nalbuphine
,3410891,signal-to-noise ratio,"Although the limit of detection was 0.3 ng/ml based on a signal-to-noise ratio of 3, the reliable limit of quantitation was 1 ng/ml (coefficient of variation 12%) using 1 ml of plasma.",Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410891/),,3,148230,DB00844,Nalbuphine
,3740151,terminal elimination half-life,"The maternal disposition of nalbuphine followed a two-compartment pharmacokinetic model, with an initial distribution phase of 4 to 20 minutes and a terminal elimination half-life of 2.4 +/- 0.4 hours.",Pharmacokinetics of nalbuphine during parturition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740151/),h,2.4,148372,DB00844,Nalbuphine
,23460034,flow rate,"The mobile phase was composed of acetonitrile and water (83:17, v/v) that contained 0.2% formic acid and 4 mm ammonium formate at a flow rate of 0.25 mL/min.",Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460034/),[ml] / [min],0.25,163951,DB00844,Nalbuphine
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],3.1,171644,DB00844,Nalbuphine
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],8.4,171645,DB00844,Nalbuphine
greater,8738033,recoveries,The recoveries of nalbuphine and ethylmorphine (internal standard) were greater than 86%.,Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),%,86,175921,DB00844,Nalbuphine
,8738033,signal-to-noise ratio,The limit of quantitation was 0.75 ng/ml of plasma based on a signal-to-noise ratio of 3.,Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),,3,175922,DB00844,Nalbuphine
,8738033,distribution,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,0.9,175923,DB00844,Nalbuphine
,8738033,distribution,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,5.8,175924,DB00844,Nalbuphine
,8738033,distribution,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,157,175925,DB00844,Nalbuphine
,8738033,distribution,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,3.5,175926,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,0.9,175927,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,5.8,175928,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,157,175929,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),[ml] / [min],370,175930,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,3.5,175931,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,28,175932,DB00844,Nalbuphine
,8738033,elimination half-lives,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,117,175933,DB00844,Nalbuphine
,8738033,plasma clearance,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,5.8,175934,DB00844,Nalbuphine
,8738033,plasma clearance,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,157,175935,DB00844,Nalbuphine
,8738033,plasma clearance,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),[ml] / [min],370,175936,DB00844,Nalbuphine
,8738033,plasma clearance,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),min,117,175937,DB00844,Nalbuphine
,8738033,plasma clearance,"The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.",Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738033/),[ml] / [min],21 166,175938,DB00844,Nalbuphine
,9106032,recoveries,"Experiments with spiked plasma samples resulted in recoveries of 95 +/- 5.4% and 98 +/- 6.2% for nalbuphine and 6-monoacetylmorphine, respectively.",Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9106032/),%,95,183433,DB00844,Nalbuphine
,9106032,recoveries,"Experiments with spiked plasma samples resulted in recoveries of 95 +/- 5.4% and 98 +/- 6.2% for nalbuphine and 6-monoacetylmorphine, respectively.",Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9106032/),%,98,183434,DB00844,Nalbuphine
,9106032,detection limit,The detection limit for 500 microliters plasma sample was 0.02 ng/ml and the limit of quantification 0.1 ng/ml (C.V. = 12.4%).,Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9106032/),[ng] / [ml],0.02,183435,DB00844,Nalbuphine
,7704197,recoveries,"The recoveries of nalbuphine and 6-monoacetylmorphine, used as internal standard, were close to 85%.",Rapid and sensitive high-performance liquid chromatographic assay for nalbuphine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704197/),%,85,188114,DB00844,Nalbuphine
,33942343,Cmax,"The maximum concentration (Cmax ) and area under concentration-time curve (AUC0-t ) values of nalbuphine in the single-injection and PCA groups were as follows: Cmax , 81.3 ± 24.7 and 39.8 ± 6.4 ng/ml, respectively; moreover, AUC0-t , 110.3 ± 19.5 and 128.3 ± 23.0 h ng/ml, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),[ng] / [ml],81.3,209905,DB00844,Nalbuphine
,33942343,Cmax,"The maximum concentration (Cmax ) and area under concentration-time curve (AUC0-t ) values of nalbuphine in the single-injection and PCA groups were as follows: Cmax , 81.3 ± 24.7 and 39.8 ± 6.4 ng/ml, respectively; moreover, AUC0-t , 110.3 ± 19.5 and 128.3 ± 23.0 h ng/ml, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),[ng] / [ml],39.8,209906,DB00844,Nalbuphine
,33942343,AUC0-t,"The maximum concentration (Cmax ) and area under concentration-time curve (AUC0-t ) values of nalbuphine in the single-injection and PCA groups were as follows: Cmax , 81.3 ± 24.7 and 39.8 ± 6.4 ng/ml, respectively; moreover, AUC0-t , 110.3 ± 19.5 and 128.3 ± 23.0 h ng/ml, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),[h·ng] / [ml],110.3,209907,DB00844,Nalbuphine
,33942343,AUC0-t,"The maximum concentration (Cmax ) and area under concentration-time curve (AUC0-t ) values of nalbuphine in the single-injection and PCA groups were as follows: Cmax , 81.3 ± 24.7 and 39.8 ± 6.4 ng/ml, respectively; moreover, AUC0-t , 110.3 ± 19.5 and 128.3 ± 23.0 h ng/ml, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),[h·ng] / [ml],128.3,209908,DB00844,Nalbuphine
,33942343,effective analgesic concentration durations (EACDs),"The effective analgesic concentration durations (EACDs) for the two administration methods were 1.39 ± 0.64 and 1.96 ± 0.91 h, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),h,1.39,209909,DB00844,Nalbuphine
,33942343,effective analgesic concentration durations (EACDs),"The effective analgesic concentration durations (EACDs) for the two administration methods were 1.39 ± 0.64 and 1.96 ± 0.91 h, respectively.",Pharmacokinetic comparison of nalbuphine with single injection and patient-controlled analgesia mimic method in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33942343/),h,1.96,209910,DB00844,Nalbuphine
,34173038,retention times,"After a simple protein precipitation step, samples are separated on 2-μm C18 column kept at 40 °C, using isocratic flow of 80% methanol in pH 9.5 ammonium formate buffer, and retention times were about 1.8 and 2.9 min for galantamine and nalbuphine, respectively.",LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats' brain homogenate and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173038/),min,1.8,210869,DB00844,Nalbuphine
,34173038,retention times,"After a simple protein precipitation step, samples are separated on 2-μm C18 column kept at 40 °C, using isocratic flow of 80% methanol in pH 9.5 ammonium formate buffer, and retention times were about 1.8 and 2.9 min for galantamine and nalbuphine, respectively.",LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats' brain homogenate and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173038/),min,2.9,210870,DB00844,Nalbuphine
,21337353,flow rate,The flow rate was 0.3 mL/min and the total run time was 2 min.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),[ml] / [min],0.3,217734,DB00844,Nalbuphine
,21337353,total run time,The flow rate was 0.3 mL/min and the total run time was 2 min.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),min,2,217735,DB00844,Nalbuphine
,21337353,m/,The mass transitions were m/z 358 → 340 for nalbuphine and m/z 328 → 310 for naloxone.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,358,217736,DB00844,Nalbuphine
,21337353,m/,The mass transitions were m/z 358 → 340 for nalbuphine and m/z 328 → 310 for naloxone.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,340,217737,DB00844,Nalbuphine
,21337353,signal-to-noise ratio,The lower limit of quantitation was set at 0.5 ng/mL plasma based on an average signal-to-noise ratio of 44.79.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,44.79,217738,DB00844,Nalbuphine
,8706774,plasma half-life,An estimated plasma half-life of 4.1 h was calculated from two determinations in the neonate based on the assumption of a monoexponential decay of nalbuphine concentrations.,Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706774/),h,4.1,229355,DB00844,Nalbuphine
,3196391,total amount,"During a 24-h period, the total amount of nalbuphine excreted in the breast milk was 2.3 micrograms (mean value), which is equivalent to 0.012% of the dosage.",[Elimination of nalbuphine in human milk]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196391/),μg,2.3,231026,DB00844,Nalbuphine
,3196391,excreted,"During a 24-h period, the total amount of nalbuphine excreted in the breast milk was 2.3 micrograms (mean value), which is equivalent to 0.012% of the dosage.",[Elimination of nalbuphine in human milk]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196391/),μg,2.3,231027,DB00844,Nalbuphine
,12711158,relative bioavailability,"The in vivo pharmacokinetic studies after s.c. injection of microspheres into rabbits showed sustained plasma NA-time profiles, with approximately 104.7, 67.2, and 41.0% relative bioavailability for microspheres loaded with nalbuphine propionate (NAP), nalbuphine pivalate (NPI), and nalbuphine decanoate (NDE), respectively.",Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711158/),%,104.7,241260,DB00844,Nalbuphine
,12711158,relative bioavailability,"The in vivo pharmacokinetic studies after s.c. injection of microspheres into rabbits showed sustained plasma NA-time profiles, with approximately 104.7, 67.2, and 41.0% relative bioavailability for microspheres loaded with nalbuphine propionate (NAP), nalbuphine pivalate (NPI), and nalbuphine decanoate (NDE), respectively.",Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711158/),%,67.2,241261,DB00844,Nalbuphine
,12711158,relative bioavailability,"The in vivo pharmacokinetic studies after s.c. injection of microspheres into rabbits showed sustained plasma NA-time profiles, with approximately 104.7, 67.2, and 41.0% relative bioavailability for microspheres loaded with nalbuphine propionate (NAP), nalbuphine pivalate (NPI), and nalbuphine decanoate (NDE), respectively.",Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711158/),%,41.0,241262,DB00844,Nalbuphine
,9106045,extraction recovery,The extraction recovery was 91.1 +/- 3.7%.,Determination of nalbuphine in human plasma by high-performance liquid chromatography with electrochemical detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9106045/),%,91.1,245927,DB00844,Nalbuphine
,3580238,elimination half-life,"Disposition was best described as a triexponential function, with a mean elimination half-life of 135.5 min.",Disposition of nalbuphine in patients undergoing general anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580238/),min,135.5,269992,DB00844,Nalbuphine
,3580238,MRT,"Mean residence time, clearance, and volumes of distribution, Vss and V beta, were determined by a model independent method, and gave mean values of 149.7 min (MRT), 1095 ml min-1 (ClP), 159.9 litre (Vss) and 207.1 litre (V beta).",Disposition of nalbuphine in patients undergoing general anaesthesia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580238/),min,149.7,269993,DB00844,Nalbuphine
,3580238,ClP,"Mean residence time, clearance, and volumes of distribution, Vss and V beta, were determined by a model independent method, and gave mean values of 149.7 min (MRT), 1095 ml min-1 (ClP), 159.9 litre (Vss) and 207.1 litre (V beta).",Disposition of nalbuphine in patients undergoing general anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580238/),[ml] / [min],1095,269994,DB00844,Nalbuphine
,3580238,Vss,"Mean residence time, clearance, and volumes of distribution, Vss and V beta, were determined by a model independent method, and gave mean values of 149.7 min (MRT), 1095 ml min-1 (ClP), 159.9 litre (Vss) and 207.1 litre (V beta).",Disposition of nalbuphine in patients undergoing general anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580238/),l,159.9,269995,DB00844,Nalbuphine
,3580238,V beta,"Mean residence time, clearance, and volumes of distribution, Vss and V beta, were determined by a model independent method, and gave mean values of 149.7 min (MRT), 1095 ml min-1 (ClP), 159.9 litre (Vss) and 207.1 litre (V beta).",Disposition of nalbuphine in patients undergoing general anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580238/),l,207.1,269996,DB00844,Nalbuphine
